Complex Psychopharmacology Case Review

Ashwini Srinivasamohan (35F)

DOB: 08/27/1990 | Visit: March 5, 2026

Collaborating Provider: Stacy Pascarella, APRN

Reviewer: Psychiatric MD Collaborator | March 19, 2026

Assessment: Reasonable Course with Specific Enhancements

1 / 12

Diagnostic Formulation: 6 Primary + 1 Consideration

Diagnosis	Code	Key Features
Bipolar II Depression	F31.32	Moderate, stable
ADHD Unspecified	F90.9	Partial response, afternoon crash
Generalized Anxiety	F41.1	GAD-7: 11 (moderate)
Alcohol Dependence, Remission	F10.21	2 drinking episodes since last visit
Binge Eating Disorder	F50.819	PHQ-9 Item 5: 3/3
Drug-Induced Dyskinesia	G24.01	AIMS: 7 (minimal), stable

Additional Consideration: Nightmare Disorder (F51.5) — persistent despite prazosin

2 / 12

Current Medication Regimen

Medication	Dose	Indication
Venlafaxine XR	187.5mg daily	Depression + Anxiety
Lamotrigine	100mg daily	Bipolar mood stabilization
Adderall IR	30mg daily	ADHD (converting to XR)
Naltrexone	50mg daily	Alcohol use disorder
Prazosin	2mg nightly	Nightmares (questionable efficacy)
Doxepin	10mg nightly	Sleep maintenance
Gabapentin	300mg PRN	Anxiety (PRN)
Propranolol	20mg BID PRN	Performance anxiety

3 / 12

Critical Issue #1: Lamotrigine Subtherapeutic Dosing

Current: 100mg daily

Target for Bipolar Depression: 200mg daily

Evidence Base:

Calabrese et al. (1999): Lamotrigine 200mg superior to placebo for bipolar depression
Geddes et al. (2009): 200mg standard maintenance dose
Current 100mg provides partial protection at best

Recommendation:

Week 1-2: Continue 100mg
Week 3-4: Increase to 150mg
Week 5+: Target 200mg maintenance
Monitor for rash (Stevens-Johnson risk)

4 / 12

Critical Issue #2: Stimulant Formulation Optimization

Problem: Afternoon Crash on IR Formulation

IR duration: 4-6 hours | XR duration: 10-12 hours

Clinical Rationale for Conversion:

Patient reports "wearing off" by early afternoon
Partial symptom coverage limits functional impairment
XR reduces peak/trough fluctuations
Lower abuse potential with XR formulation

Conversion Protocol:

Adderall IR 30mg → Adderall XR 30mg (1:1 conversion)

Monitor: Sleep onset latency, evening irritability, medication adherence

5 / 12

Critical Issue #3: Venlafaxine in Bipolar II

Risk: Antidepressant-Induced Mood Elevation

SNRIs carry higher risk than SSRIs in bipolar disorder

Risk Mitigation Currently in Place:

✅ Lamotrigine (partial mood stabilizer coverage)
✅ No current hypomanic symptoms
✅ Patient educated on warning signs

Monitoring Protocol:

Weekly mood ratings for 4 weeks post-dose change
YMRS if any elevated symptoms emerge
Family collateral on sleep and activity changes
Immediate venlafaxine reduction if mixed features develop

6 / 12

Required Monitoring Protocols

Risk Domain	Monitoring Strategy	Frequency
Tardive Dyskinesia	AIMS assessment	Quarterly
Liver Function	CBC, CMP, LFTs	Baseline, 1mo, 3mo, then q6mo
Mood Stability	PHQ-9, GAD-7, symptom diary	Weekly during titration
ADHD Response	ASRS, functional outcomes	Monthly
Alcohol Use	AUDIT-C, drinking diary	Each visit

7 / 12

Questionable Efficacy: Prazosin for Nightmares

Current Status: Persistent Nightmares Despite Treatment

Dose: 2mg nightly | Duration: Adequate trial | Outcome: Minimal benefit

Differential Considerations:

PTSD-related nightmares (prazosin most effective here)
REM sleep behavior disorder
Medication-induced vivid dreams (venlafaxine, naltrexone)
Nightmare disorder as distinct diagnostic entity

Suggested Approach:

4-week discontinuation trial with nightmare diary
If nightmares persist off prazosin: Evaluate for PTSD features
Consider sleep study if REM behavior disorder suspected
Image Rehearsal Therapy (IRT) as non-pharmacologic alternative

8 / 12

Risk Stratification Summary

Risk Domain	Level	Key Mitigation
Tardive Dyskinesia	🟢 Low	Stable AIMS score; quarterly monitoring
Antidepressant Mania	🟡 Moderate	Mood stabilizer coverage; weekly monitoring
Liver Toxicity (Naltrexone)	🟡 Moderate	Scheduled LFTs; patient education
Stimulant Misuse	🟢 Low	XR formulation; monthly follow-up
Alcohol Relapse	🟡 Moderate	Naltrexone adherence; counseling support

9 / 12

Priority Recommendations Summary

🔴 HIGH PRIORITY

Lamotrigine Optimization: 100mg → 200mg via staged titration

Rationale: Subtherapeutic for bipolar depression; evidence supports 200mg target

🟡 MEDIUM PRIORITY

Stimulant Conversion: Adderall IR → XR 30mg

Rationale: Eliminate afternoon crash; improve functional coverage

🟡 MEDIUM PRIORITY

Prazosin Trial: 4-week discontinuation with nightmare diary

Rationale: Questionable efficacy; clarify true nightmare etiology

10 / 12

Key Teaching Points

Complex Polypharmacy Requires Systematic Review: 8 medications across 6 diagnoses necessitates regular comprehensive assessment
Evidence-Based Dosing Matters: Lamotrigine 100mg vs 200mg represents subtherapeutic vs therapeutic for bipolar depression
Formulation Selection Impacts Outcomes: IR vs XR stimulants: same molecule, different pharmacokinetics, different clinical results
Risk Stratification is Dynamic: Venlafaxine appropriateness depends on mood stabilizer coverage and monitoring intensity
Question Efficacy When Evidence Lacks: Persistent nightmares despite prazosin warrants reassessment, not automatic dose increase
Monitoring Protocols are Treatment: Scheduled LFTs, AIMS, and mood ratings are as essential as prescriptions

11 / 12

Summary: Reasonable Course, Specific Enhancements

Overall Assessment: APPROVED with Recommendations

Comprehensive medication management with strong patient-centered care

Next Steps:

Implement lamotrigine titration to 200mg
Convert stimulant to XR formulation
Prazosin discontinuation trial with monitoring
Continue all monitoring protocols
Reassess in 4-6 weeks

From: Psychiatric MD Collaborator
To: Stacy Pascarella, APRN
Date: March 19, 2026

12 / 12